TScan Pauses Its Phase 3 for Lack of Money, Cuts 75% of Staff and Pivots Back to the Solid-Tumor Program It Shelved Ten Months Ago

by Ellis Vance · September 2, 2026

Small-Cap Markets Correspondent, The SmallCap Signal

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced a strategic reorganization on Sept. 2 that reduces its workforce by approximately 75%, pauses further enrollment in its Phase 3 ALLOHA-2 study of TSC-101, and redirects what remains of the company toward an in vivo-engineered TCR-T programme in solid tumours.

The reason given for stopping enrollment is the one that carries the most weight for a clinical-stage company: capital. The Sept. 2 release attributes the pause to insufficient capital, not to a safety signal and not to a futility finding. That distinction matters. A trial halted on data tells you something about the drug. A trial halted on money tells you something about the balance sheet, and leaves the scientific question exactly where it was.

The timing is unusually compressed. In its second-quarter release on Aug. 12, TScan reported that the first patient had been dosed in the Phase 3 ALLOHA-2 trial and that completion of enrollment and topline data were expected in mid-2028. Three weeks later the trial is no longer enrolling. The company said it will continue to track the seven patients already enrolled on the treatment arm of ALLOHA-2 and the 13 patients in Cohort C of the Phase 1 ALLOHA study, with updated Cohort C data due in the fourth quarter of 2026 and data on all patients treated with the commercial-ready manufacturing process in the second quarter of 2027.

What the 75% buys

The reorganization is expected to deliver cumulative cost savings of $55.0 million through the end of 2027, according to the Sept. 2 release, which says available cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund planned operations into the fourth quarter of 2027. Set that against the guidance in the Aug. 12 release, which drew on the same June 30 balance sheet — $100.2 million in cash and cash equivalents, excluding $5.0 million of restricted cash — and said existing cash resources would fund the then-current operating plan into the second quarter of 2027. The two statements are not on an identical basis, since only the September figure explicitly includes marketable securities.

Cutting three-quarters of the staff and stopping a Phase 3, in other words, extends the runway by roughly two quarters on the company's own numbers. That is not a rounding error, but neither is it the multi-year cushion the scale of the cut might imply, and it is a useful measure of how much of TScan's burn was going into the pivotal trial.

There is also a debt clock running. The Aug. 12 release disclosed that the company did not achieve certain non-covenant related milestones by June 30, 2026 under its debt agreement, which triggers the commencement of a two-year term loan amortization beginning in the fourth quarter of 2026. Principal repayment beginning inside the runway window is a constraint on how freely the remaining cash can be spent.

A reversal, not a refinement

The strategic content of Sept. 2 is close to the mirror image of what TScan told investors on Nov. 3, 2025. On that date the company said the FDA had agreed to a pivotal design for TSC-101 — a study mirroring the Phase 1 ALLOHA trial, using a biologically assigned internal control arm instead of an external control arm, with relapse-free survival as the primary endpoint and patients stratified by HLA-A*02:01 status for arm assignment — and simultaneously announced it was pausing further enrollment in its PLEXI-T solid-tumour study and proceeding instead with preclinical development of in vivo engineering for solid tumours, in order to concentrate clinical development on heme.

That November prioritisation came with a workforce reduction of roughly 30%, affecting 66 employees, and with a specific promise from Chief Financial Officer Jason Amello: annual cost savings of approximately $45.0 million in 2026 and 2027, and a cash runway extended into the second half of 2027. Ten months later the runway guidance is into the fourth quarter of 2027 — broadly the same destination — but the programme it was meant to fund is the one being paused, and the runway is being defended by a second, much larger cut.

The solid-tumour work TScan is returning to is not the same asset it shelved. Rather than the ex vivo autologous approach behind PLEXI-T, the company is advancing in vivo-engineered TCR-T candidates against PRAME and MAGE-A4, both now in IND-enabling studies — the same in vivo route the November 2025 release had already flagged as the destination for its preclinical solid-tumour effort. TScan argues this route addresses the manufacturing cost, treatment delay and lymphodepletion burdens of conventional autologous cell therapy. Preclinical data are slated for the first quarter of 2027, a first IND filing for the third quarter of 2027, and Phase 1 initiation for the fourth quarter of 2027.

Chief Executive Gavin MacBeath said in the release that because the company is limited by its ability to access the substantial capital resources needed to complete the Phase 3 trial, it had made the difficult decision to allocate its resources to programmes it believes better allow it to create value for all stakeholders, including patients. TScan said it intends to continue collecting safety and efficacy data on the heme programme while exploring strategic partnerships that could move it forward, and said it is evaluating strategic partnerships for its HLA-B*27-associated autoimmune disorders work, which includes ankylosing spondylitis. No partner, term sheet or process timeline was named.

The financial trajectory behind all of this was already tightening. For the second quarter of 2026 TScan reported revenue of $1.1 million against $3.1 million a year earlier, research and development expense of $23.4 million versus $32.6 million, general and administrative expense of $8.1 million versus $9.1 million, and a net loss of $30.4 million versus $37.0 million. Pro forma shares outstanding, combining common stock and pre-funded warrants, stood at 130,025,962 as of June 30, 2026.

The company did report continuing clinical signal from the programme it is pausing: TScan said all 13 of the patients currently being tracked show complete donor chimerism, including two who had previously relapsed, and that TSC-101 infusions continue to be generally well tolerated. Whether that is enough to attract a partner willing to fund a Phase 3 that TScan itself cannot is the question the next two data updates will be asked to answer.

This article reports the company's disclosures and does not constitute a recommendation with respect to any security.